Inventiva S.A. (IVA) Q4 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Inventiva Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.029 -- 00:00:05.154 Thank you, operator, and welcome to everybody to this full year 2022 financial 00:00:05.154 -- 00:00:07.154 results. 00:00:07.356 -- 00:00:12.000 As usual, I will be making with my colleague forward-looking statements, so please have 00:00:12.000 -- 00:00:18.284 a look at the regulatory documentation that is available on our website. 00:00:18.306 -- 00:00:23.812 In terms of speakers today, I'm very happy, as usual, to have Pierre with us, 00:00:23.812 -- 00:00:28.979 our CSO and co-founder. michael our cmo will 00:00:28.979 -- 00:00:33.982 go through an update of our three important clinical trials with with an ephemeral 00:00:33.982 -- 00:00:39.164 of course the phase three but also two phase two that are ongoing and then john will 00:00:39.164 -- 00:00:41.245 conclude the presentation 00:00:41.245 -- 00:00:44.546 with an update on the financials 00:00:44.767 -- 00:00:49.858 of course at the end of the session you we will have a q a session 00:00:49.858 -- 00:00:54.482 So let me give you, first of all, some highlights for the full year. 00:00:54.482 -- 00:00:59.506 So let's start with our lead program, NANI, in NASH, and 00:00:59.506 -- 00:01:04.931 start with Native 3, where we've been, I would say, very happy to 00:01:04.931 -- 00:01:10.996 work and extend, to develop the Phase 3 in 23 countries. 00:01:10.996 -- 00:01:15.038 And now we have more than 350 clinical 00:01:15.038 -- 00:01:20.041 sites that are active and more than 300 that have screened at 00:01:20.041 -- 00:01:22.422 least a patient. 00:01:22.422 -- 00:01:28.466 We have throughout the year, and we continue to do so, implemented a series of measures 00:01:28.466 -- 00:01:31.267 to boost enrollment. 00:01:31.267 -- 00:01:35.098 And I would say that this continues thr...